It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Naturally occurring canine invasive urinary carcinoma (iUC) closely resembles human muscle invasive bladder cancer in terms of histopathology, metastases, response to therapy, and low survival rate. The heterogeneous nature of the disease has led to the association of large numbers of risk loci in humans, however most are of small effect. There exists a need for new and accurate animal models of invasive bladder cancer. In dogs, distinct breeds show markedly different rates of iUC, thus presenting an opportunity to identify additional risk factors and overcome the locus heterogeneity encountered in human mapping studies. In the association study presented here, inclusive of 100 Shetland sheepdogs and 58 dogs of other breeds, we identify a homozygous protein altering point mutation within the NIPAL1 gene which increases risk by eight-fold (OR = 8.42, CI = 3.12–22.71), accounting for nearly 30% of iUC risk in the Shetland sheepdog. Inclusion of six additional loci accounts for most of the disease risk in the breed and explains nearly 75% of the phenotypes in this study. When combined with sequence data from tumors, we show that variation in the MAPK signaling pathway is an overarching cause of iUC susceptibility in dogs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 National Institutes of Health, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Center, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 University of Rennes, Institut de Génétique et Développement de Rennes, CNRS-UMR6290, Rennes, France (GRID:grid.410368.8) (ISNI:0000 0001 2191 9284)
3 Purdue University, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, West Lafayette, USA (GRID:grid.169077.e) (ISNI:0000 0004 1937 2197)
4 National Institutes of Health, Center for Biomedical Informatics & Information Technology, National Cancer Institute, Frederick, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
5 Purdue University, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, West Lafayette, USA (GRID:grid.169077.e) (ISNI:0000 0004 1937 2197); Purdue University Center for Cancer Research, West Lafayette, USA (GRID:grid.516079.c) (ISNI:0000 0004 0404 9602)